News & Events

June 2013

Share
masthead_enewsletter_CDINotebook

JUNE 2013

view_agenda

Welcome to our monthly enewsletter, CDI Notebook, focused on keeping you abreast of the latest innovations using CDI’s iCell® and MyCell® products.

In this issue:
Publications
Presentations/Posters
Videos
Conference News
Press Releases

horizontal rule

Publications

Comparison of Electrophysiological Data from Human Induced Pluripotent Stem Cell Derived Cardiomyocytes (hiPSC-CMs) to Functional Pre-clinical Safety Assays. GSK researchers demonstrate that iCell Cardiomyocytes act as a valid, relevant, and translatable pre-clinical model to study drug-induced electrophysiological changes for early safety pharmacology screening.

Harris K, Aylott M, Cui Y, Louttit JB, McMahon NC, and Sridhar A. (2013) Toxicol Sci. DOI: 10.1093/toxsci/kft113

Article>>

horizontal rule

Presentations/Posters

workshop_data

iCell Workshop: Advances in Human iPSC-derived Cell Models for Phenotypic Screening & Toxicity Studies. View presentations from our recent iCell workshop to learn how researchers employ CDI’s human iPSC-derived technology in safety testing, drug discovery, and disease modeling research.

horizontal rule

Videos

EC_video

Capillary-like Network Formation of iCell Endothelial Cells. Video demonstrates the native functionality exhibited by iCell Endothelial Cells, which form 3D capillary-like networks when encapsulated in a synthetic matrix over days 2 – 3 in culture, suggesting applications in vascular therapeutic development and tissue engineering research.

Video>>

horizontal rule

Conference News

jthomson_caption

ISSCR (Jun 12 – 15, Boston, MA, Booth 609). iCell and MyCell technology will be discussed at these presentations:

  • Generating Collections of Human iPSC and ESC Lines: Establishing Best Practices for Sharing Protocols and Cell Lines
    Jun 12 | 9:00 – 11:00 am | Rm 254
  • Inner Cell Mass Hysteria – A Personal Historical Perspective on the Derivation of Human Pluripotent Stem Cells
    Jun 12 | 1:00 – 1:50 pm | Plenary Hall B1
  • Predictive High-throughput Assays for Toxicity Assessment Using iPSC-derived Cell Models
    Jun 13 | 12:00 – 1:00 pm | Rm 255
  • Human iPSC-derived Cardiomyocytes Provide a Relevant Model of Cardiac Hypertrophy for Use in Phenotypic Screening and Drug Discovery (T-3142)
    Jun 13 | 6:00 – 8:00 pm | Poster Hall
  • Thyroid Hormone Pathway Modulation: Effect on Stem Cell-derived Cardiomyocyte Maturation (T-3144)
    Jun 13 | 6:00 – 8:00 pm | Poster Hall
  • Characterization of the MicroRNA Expression Profiles of iPS Cells and Their Derivatives by Massively Parallel Sequencing (F-2053)
    Jun 14 | 6:00 – 8:00 pm | Poster Hall
  • Predictive High-throughput Assays for Hepatotoxicity and Cardiac Physiology Using Induced Pluripotent Stem Cell (iPSC)-derived Cell Models (F-3153)
    Jun 14 | 6:00 – 8:00 pm | Poster Hall
  • A High Content Screen for Compounds That Modulate Neurite Outgrowth and Retraction Using Human Induced Pluripotent Stem Cell Derived Neurons (F-3184)
    Jun 14 | 6:00 – 8:00 pm | Poster Hall

Details>>


Cell Based Assays for Screening Workshop
(Jun 11 – 13, Hamburg, Germany). Includes hands-on sessions using iCell products in cardiac hypertrophy, neurite outgrowth, and mitochondrial toxicity assays.

Details>>

MCS Microelectrode Array Workshop 2013: Cardiac Applications on Microelectrode Arrays (Jun 20, Reutlingen, Germany). Perform drug profiling and safety pharmacology testing on iCell Cardiomyocytes using multiwell microelectrode arrays.

Details>>

xCELLigence Cardio User Symposium (Jul 12 – 13, Arlington, VA). Join us at the following session:

  • Arrhythmia and QT Prolongation Prediction Using iCell Cardiomyocytes: Past, Present, and Future
    Jul 13 | 10:50 – 11:25 am

Details>>

CDI 2nd Annual User Group Meeting (Aug 26 – 28, Madison, WI). Join fellow researchers to discuss innovations using iPSC-derived cells in disease modeling and tissue engineering, toxicity testing, and drug discovery. View the agenda and register today!

Details>>

horizontal rule

Press Releases

Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents. CDI now offers access to a number of human disease models, including cardiomyopathies and arrhythmias, vision disorders, neurological disorders, and muscular dystrophies, and the company is working on neurodegenerative disorders and drug-induced liver injury (DILI) as well. In addition, CDI has the capability to use Life Technologies’ GeneArt® Precision TALs (TALENs) and Sigma’s CompoZr® ZFN technologies to perform genetic engineering, for example to introduce or correct a specific mutation, thus creating human disease models and isogenic controls.

Article>>

horizontal rule
© 2014 Cellular Dynamics International, Inc.
525 Science Drive, Madison, WI 53711
+1 (608) 310-5100 or toll-free (877) 310-6688
www.cellulardynamics.com
Follow us: facebook16x16px_green linkedin16x16px_green twitter16x16px_green youtube16x16px_green